Asset Details
Do you wish to reserve the book?
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Do you wish to request the book?
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
2011
Overview
Idiopathic pulmonary fibrosis is characterized by rapid loss of vital capacity, disability, and death. There are no effective treatments. Although this study failed to meets its primary end point, the data show therapeutic efficacy at a cost of substantial GI toxicity.
Idiopathic pulmonary fibrosis is a debilitating disease characterized by destruction of the gas-exchanging regions of the lung.
1
Its pathogenesis is thought to involve aberrant wound healing mediated by multiple signaling pathways, resulting in progressive lung injury and scarring.
1
Symptoms, including cough and dyspnea, limit physical activity and reduce the patient's quality of life and independence.
2
The course of the disease is difficult to predict, but it generally involves progressive deterioration, with a median survival time of 2.5 to 3.5 years after diagnosis.
3
Unpredictable acute exacerbations occur in some patients and are often fatal.
3
,
4
BIBF 1120 is a potent intracellular . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Alanine Transaminase - blood
/ Aspartate Aminotransferases - blood
/ Biological and medical sciences
/ Disease
/ Enzyme Inhibitors - adverse effects
/ Enzyme Inhibitors - therapeutic use
/ Female
/ Fibrosis
/ Humans
/ Idiopathic Pulmonary Fibrosis - drug therapy
/ Idiopathic Pulmonary Fibrosis - physiopathology
/ Liver
/ Male
/ Protein-Tyrosine Kinases - antagonists & inhibitors
/ Respiratory system : syndromes and miscellaneous diseases
/ Writers
We currently cannot retrieve any items related to this title. Kindly check back at a later time.